The removal of nimpenem and cilastatin by hemodialysis was studied in 14 (for imipenem) and 6 (for cilastatin) subjects. FoUowing intravenous infusion of imipenem and cilastatin at a combined concentration of 10 mg/kg of body weight, drug levels in plasma were determined serially during off-and on-hemodialysis periods, which were 2 and 4 h, respectively. The biexponential decay of the drug levels in plasma was evident in each subject for both imipenem and cilastatin. Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min. Hemodialysis clearance of imipenem and cilastatin was calculated by five different methods, each with intrinsic assumptions. The mean hemodialysis clearance of niipenem was estimated to be 74.08 + 13.29 ml/min, and that of cilastatin was estimated to be 65.0 + 8.6 ml/min, after consideration of various methodological limitations. It was estimated that in a hypothetical anephric patient weighing 60 kg, a 4-h hemodialysis treatment would remove 54.8% of the imipenem and 62.9% of the cilastatin present in the body at the start of dialysis.
Imipenem is the first member of a new class of beta-lactam antibiotics, the carbapenems, to become clinically available. It is coadministered with an equal amount of cilastatin to prevent its inactivation by renal dehydropeptidase I. Both imipenem and cilastatin are largely excreted in the urine when administered to humans with normal renal function, and the accumulation of these drugs can be anticipated in subjects with decreased renal function (2, 3) . The pharmacokinetic profiles of imipenem and cilastatin in renal failure have been studied in detail previously (4, 11) . During concomitant drug therapy, the removal of a drug by hemodialysis may be significant enough to require a dosage supplement to ensure adequate therapeutic efficacy. The present study was conducted to evaluate the effect of hemodialysis on the pharmacokinetics of imipenem and cilastatin, since previous reports on this issue are limited in number and detail (1, 4, 11) .
MATERIALS AND METHODS Antibiotics. Imipenem and cilastatin (both from Banyu Pharmaceutical Co., Ltd., Tokyo, Japan) were used in the study.
Subjects. Fifteen adult patients (14 males and 1 female) in end-stage renal failure and receiving maintenance hemodialysis for at least 1 year were studied. All gave their informed consent to participate, and the protocol for the study was approved by the Ethical Committee at the School of Medicine, Keio University. All patients were stable with respect to their renal function and had normal hepatic function, as assessed by standard clinical laboratory tests. None were receiving any antimicrobial agents. Although all were studied with the same protocol, complete pharmacokinetic studies of both imipenem and cilastatin were possible in only five patients. The kinetics of imipenem were studied in only nine patients, since their hematocrit levels were relatively low * Corresponding author.
and it was elected to minimize the amount of blood sampling. For the remaining one patient, only cilastatin data were included in the kinetic analysis, because of a laboratory accident encountered during the imipenem assay. The average age, body weight, and height of the patients in whom imipenem kinetics were studied were 48 + 18 years, 53.9 ± 7.4 kg, and 164.9 ± 4.9 cm, respectively. The average age, body weight, and height of the patients in whom cilastatin kinetics were studied were 58 ± 8 years, 52.8 ± 10.0 kg, and 167.7 ± 7.0 cm, respectively.
Procedure. Each subject received an intravenous dose of 10 mg of imipenem dissolved in 200 ml of normal saline per kg of body weight over exactly 30 min by an infusion pump device which also delivered an equal amount of cilastatin. Blood samples were drawn before, immediately after, and at 5, 10, 20, 30, 60, 90 , and 120 min after the termination of the infusion. Hemodialysis was initiated at 120 min and was continued for the next 4 h. Blood samples were consecutively drawn simultaneously from the arterial and the venous lines to the dialyzer at 15 and 30 min and at 1, 2, 3, and 4 h after the initiation of hemodialysis. Together with each blood sampling, stopwatch-timed outflow dialysate samples were also collected and the blood flow rate through the dialyzer was determined by the number of blood pump revolutions per unit of time, with an adjustment to a previous calibration by the bubble transit time method (9) . In addition, the drug concentrations in the entire outflow dialysate (pooled) during the dialysis session were determined. The dialyzer used was RENNEK-A-1OM (Kuraray Co., Ltd., Osaka, Japan), a cuprophane hollow-fiber dialyzer with a membrane thickness of 11 (6) . Cilastatin concentrations in plasma and dialysate were determined by high-pressure liquid chromatography with S-(p-methylbenzyl)-L-cysteine and S-benzyl-L-cysteine as internal standards for the plasma and dialysate assays, respectively (5) . A concentration of imipenem as low as 0.1 ,ug/ml and a concentration of cilastatin as low as 0.5 ,ug/ml could be measured by these methods. The interassay coefficients of variation were less than 5% (0.1 to 100 ,ug/ml) for imipenem and less than 7% (0.5 to 100 ,ug/ml) for cilastatin.
Pharmacokinetic analysis. One-and two-compartment open models with parallel intrinsic and dialysis clearances were tested to describe the plasma concentration-time profile of imipenem-cilastatin, and the two-compartment open model was judged to be optimal by the Akaike information criterion in all subjects (12) . In this model, the concentrations of imipenem and cilastatin as a function of time t in plasma [C(t)] can be expressed as follows ( Fig. 1 ): where to _ t < tl,
where t1 ' t < t2,
whereas,
Pharmacokinetic analysis was performed with a microcomputer with a nonlinear least-squares program written by the authors. The Damping-Gauss-Newton method was adopted for the calculations, and the reciprocal square concentration was used for weighting.
Calculation of the hemodialysis clearance. The hemodialysis clearance (CLHD) of imipenem and cilastatin was calculated by the following five different equations: Tables 1 through 4 depict the mean concentrations of imipenem and cilastatin in plasma after an intravenous infusion of a combined concentration of 10 mg/kg of body weight, together with serial drug concentrations in the dialysate outflow fluid. The biexponential decay of the drug levels in plasma was evident in each subject for both imipenem and cilastatin. The calculated pharmacokinetic parameters are summarized in Table 5 .
RESULTS
Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-lives 10 ,ug/ml for 4 h were 63.4% ± 7.3% at 37°C and 89.4% ± 7.6% at 20°C (n = 4). The rates of recovery of cilastatin studied in the same manner were 103.2% ± 7.6% at 37°C and 99.0% ± 9.0% at 20°C (n = 4).
DISCUSSION
The mean tl/2, of both imipenem and cilastatin in studies involving normal subjects has been reported to be approximately 60 min (3). Renal dysfunction results in the prolongation of the t1/2,3 of both imipenem and cilastatin. In the present study, the mean t1/2, of imipenem was 200 min and that of cilastatin was 445 min before the initiation of hemo- dialysis, and these values are comparable to those reported previously for subjects with end-stage renal failure (4, 11) . Hemodialysis clearance of a drug can be calculated by several different methods (equations 1 through 5). Inherent assumptions and sources of error in each of the clearance measurements have been discussed previously (8) . The clearance calculated by equation 1 would be accurate if the drug were removed only from the plasma, while equation 2 would be accurate if the complete and instantaneous concentration equilibrium were reached between the plasma and the erythrocyte water throughout the dialyzer. By equation 3 or 4, one can calculate hemodialysis clearance without knowing the intra-and extracellular distribution kinetics of the drug. Examination of Table 6 suggests that extraction of cilastatin by hemodialysis takes place not only from the plasma but also from the erythrocyte water, since equation 1 yielded the lowest clearance value (55.8 + 9.7 ml/min) and equation 2 yielded the highest clearance value (73.2 ± 10.8 ml/min), while equations 3, 4, and 5 yielded intermediate results. The accuracy of equations 3 and 4, however, depends upon the sensitivity of the assay in measuring drug concentrations in the dialysate outflow fluid, which usually are quite low toward the end of a dialysis session. In our assay system, concentrations of imipenem as low as 0.1 ,ug/ml and of cilastatin as low as 0.5 p,g/ml could be measured with reasonable precision. With equation 3, the mean concentration of imipenem in the outflow dialysate was 0.46 + 0.13 pg/ml at the conclusion of hemodialysis, while the corresponding value for cilastatin was 1.23 ± 0.38 pg/ml (Tables 2 and 4 VOL. 35, 1991 product of the volume of distribution of the central compartment and the elimination rate constant for hemodialysis. The latter, in turn, is calculated as the difference between the total elimination rate constants during dialysis and between dialysis sessions. Admittedly, problems inherent in model adoption and curve fitting are involved in this method, and these problems are possibly reflected in the relatively large coefficient of variation for the clearance data obtained by this method (Table 5) .
On the basis of the results given above, we believe that the hemodialysis clearance of imipenem calculated by equation 3 and that of cilastatin calculated by equation 4 are the most reliable, given various methodological limitations.
The hemodialysis clearance of imipenem and cilastatin has been reported in two previous studies. Verpooten et al. reported that these clearances were 84 + 10 ml/min for imipenem and 41 + 12 ml/min for cilastatin, determined by a method analogous to our equation 2 (11). Gibson et al., on the other hand, calculated the hemodialysis clearance by a method corresponding to our equation 1 (4) : the values reported by these authors were 68.1 ± 15.9 ml/min for imipenem and 45.6 + 19.8 ml/min for cilastatin. The same authors also calculated the hemodialysis clearance by a method identical to our equation 3: the reported values were 66.5 ± 13.2 ml/min for imipenem and 47.6 + 22.6 ml/min for cilastatin. Thus, the hemodialysis clearances of both imi- where CLHD is the hemodialysis clearance of the drug, CLb is the intrinsic body clearance of the drug, t is the duration of hemodialysis, and V is the volume of distribution (7, 10) . The volume of distribution of imipenem has been reported to be 0.23 to 0.31 liters/kg (2) . Thus, in a hypothetical anephric patient with a body weight of 60 kg, the volume of distribution can be assumed to be 16.2 liters (i.e., 0.27 liters/kg). With the regression equation relating the glomerular filtration rate to the total clearance of imipenem reported by Gibson et al. (4) , the intrinsic body clearance of the drug for this anephric patient can be estimated to be 41.4 ml/min. Assuming that the hemodialysis clearance of imipenem is 80 ml/min (Table 6) , it can be calculated by the above-described equation that conventional 4-h hemodialysis will remove 54.8% of the amount of drug present in the body at the start of dialysis. Theoretically, at least, this amount of drug should be added at the end of dialysis, although whether such an addition is necessary should be decided on the basis of clinical grounds in individual cases. The volume of distribution of cilastatin has been reported to be 0.18 to 0.27 liters/kg (4, 11) ; the intrinsic body clearance of cilastatin for an anephric patient can be estimated to be 10.7 m/min (4) . Assuming that the hemodialysis clearance of cilastatin is 65 ml/min (Table 6 ), 62.9% of the amount of drug present in the body at the start of dialysis should be removed when hemodialysis is performed for 4 h in an anephric patient weighing 60 kg.
